

# Estrid V HÃgdall

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9426346/publications.pdf>

Version: 2024-02-01

179  
papers

8,934  
citations

50273

46  
h-index

49904

87  
g-index

179  
all docs

179  
docs citations

179  
times ranked

16149  
citing authors

#	ARTICLE	IF	CITATIONS
1	Genetic and Functional Drivers of Diffuse Large B-Cell Lymphoma. <i>Cell</i> , 2017, 171, 481-494.e15.	28.9	804
2	Association Between <i>BRCA1</i> and <i>BRCA2</i> Mutations and Survival in Women With Invasive Epithelial Ovarian Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2012, 307, 382.	7.4	546
3	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. <i>Nature Genetics</i> , 2013, 45, 371-384.	21.4	493
4	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. <i>Nature Genetics</i> , 2017, 49, 680-691.	21.4	356
5	Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. <i>Lancet Oncology</i> , The, 2013, 14, 853-862.	10.7	335
6	GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. <i>Nature Genetics</i> , 2013, 45, 362-370.	21.4	326
7	Contribution of Germline Mutations in the <i>RAD51B</i> , <i>RAD51C</i> , and <i>RAD51D</i> Genes to Ovarian Cancer in the Population. <i>Journal of Clinical Oncology</i> , 2015, 33, 2901-2907.	1.6	266
8	MRI, PET/CT and ultrasound in the preoperative staging of endometrial cancer – A multicenter prospective comparative study. <i>Gynecologic Oncology</i> , 2013, 128, 300-308.	1.4	183
9	The Absolute Risk of Cervical Abnormalities in High-risk Human Papillomavirus-Positive, Cytologically Normal Women Over a 10-Year Period. <i>Cancer Research</i> , 2006, 66, 10630-10636.	0.9	182
10	<i>PALB2</i> , <i>CHEK2</i> and <i>ATM</i> rare variants and cancer risk: data from COGS. <i>Journal of Medical Genetics</i> , 2016, 53, 800-811.	3.2	174
11	Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. <i>Cancer Discovery</i> , 2016, 6, 1052-1067.	9.4	157
12	Human Papillomavirus Genotyping and p16 Expression As Prognostic Factors for Patients With American Joint Committee on Cancer Stages I to III Carcinoma of the Anal Canal. <i>Journal of Clinical Oncology</i> , 2014, 32, 1812-1817.	1.6	149
13	Tubal ligation and risk of ovarian cancer subtypes: a pooled analysis of case-control studies. <i>International Journal of Epidemiology</i> , 2013, 42, 579-589.	1.9	146
14	The diagnostic value of PET/CT for primary ovarian cancer – A prospective study. <i>Gynecologic Oncology</i> , 2007, 105, 145-149.	1.4	145
15	Epigenetic analysis leads to identification of <i>HNF1B</i> as a subtype-specific susceptibility gene for ovarian cancer. <i>Nature Communications</i> , 2013, 4, 1628.	12.8	144
16	Germline Mutation in <i>BRCA1</i> or <i>BRCA2</i> and Ten-Year Survival for Women Diagnosed with Epithelial Ovarian Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 652-657.	7.0	138
17	Sample Handling for Mass Spectrometric Proteomic Investigations of Human Sera. <i>Analytical Chemistry</i> , 2005, 77, 5114-5123.	6.5	129
18	Continuing rise in oropharyngeal cancer in a high HPV prevalence area: A Danish population-based study from 2011 to 2014. <i>European Journal of Cancer</i> , 2017, 70, 75-82.	2.8	115

#	ARTICLE	IF	CITATIONS
19	Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study. <i>International Journal of Epidemiology</i> , 2016, 45, 1619-1630.	1.9	111
20	Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. <i>Nature Communications</i> , 2013, 4, 1627.	12.8	98
21	Different Risk Factor Profiles for Mucinous and Nonmucinous Ovarian Cancer: Results from the Danish MALOVA Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007, 16, 1160-1166.	2.5	95
22	Hormone Therapy and the Impact of Estrogen Intake on the Risk of Ovarian Cancer. <i>Archives of Internal Medicine</i> , 2004, 164, 2253.	3.8	94
23	<i>BRCA1</i> and <i>BRCA2</i> Mutation Prevalence and Clinical Characteristics of a Population-Based Series of Ovarian Cancer Cases from Denmark. <i>Clinical Cancer Research</i> , 2008, 14, 3761-3767.	7.0	92
24	RNA profiles reveal signatures of future health and disease in pregnancy. <i>Nature</i> , 2022, 601, 422-427.	27.8	90
25	Cigarette smoking and risk of ovarian cancer: a pooled analysis of 21 case-control studies. <i>Cancer Causes and Control</i> , 2013, 24, 989-1004.	1.8	84
26	BRAF inhibition improves tumor recognition by the immune system. <i>Oncotmmunology</i> , 2012, 1, 1476-1483.	4.6	82
27	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. <i>Nature Communications</i> , 2016, 7, 12675.	12.8	78
28	High expression of miR-21 in tumor stroma correlates with increased cancer cell proliferation in human breast cancer. <i>Apmis</i> , 2011, 119, 663-673.	2.0	74
29	Tumour-infiltrating lymphocyte scores effectively stratify outcomes over and above p16 post chemo-radiotherapy in anal cancer. <i>British Journal of Cancer</i> , 2016, 114, 134-137.	6.4	73
30	Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study. <i>International Journal of Epidemiology</i> , 2016, 45, 884-895.	1.9	71
31	miR-345 in Metastatic Colorectal Cancer: A Non-Invasive Biomarker for Clinical Outcome in Non-KRAS Mutant Patients Treated with 3rd Line Cetuximab and Irinotecan. <i>PLoS ONE</i> , 2014, 9, e99886.	2.5	68
32	Shared genetics underlying epidemiological association between endometriosis and ovarian cancer. <i>Human Molecular Genetics</i> , 2015, 24, 5955-5964.	2.9	68
33	HE4 Tissue Expression and Serum HE4 Levels in Healthy Individuals and Patients with Benign or Malignant Tumors: A Systematic Review. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 2285-2295.	2.5	65
34	MicroRNA Biomarkers in IBD-Differential Diagnosis and Prediction of Colitis-Associated Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7893.	4.1	64
35	Unravelling in vitro variables of major importance for the outcome of mass spectrometry-based serum proteomics. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2007, 847, 30-37.	2.3	63
36	Cancer antigen 125 and prognosis. <i>Current Opinion in Obstetrics and Gynecology</i> , 2008, 20, 4-8.	2.0	62

#	ARTICLE	IF	CITATIONS
37	Differential expression of miR-139, miR-486 and miR-21 in breast cancer patients sub-classified according to lymph node status. <i>Cellular Oncology</i> (Dordrecht), 2014, 37, 215-227.	4.4	62
38	Bacterial Infection as a Likely Cause of Adverse Reactions to Polyacrylamide Hydrogel Fillers in Cosmetic Surgery. <i>Clinical Infectious Diseases</i> , 2013, 56, 1438-1444.	5.8	61
39	Pelvic Inflammatory Disease and the Risk of Ovarian Cancer and Borderline Ovarian Tumors: A Pooled Analysis of 13 Case-Control Studies. <i>American Journal of Epidemiology</i> , 2017, 185, 8-20.	3.4	61
40	Frequencies and Prognostic Role of KRAS and BRAF Mutations in Patients With Localized Pancreatic and Ampullary Adenocarcinomas. <i>Pancreas</i> , 2012, 41, 759-766.	1.1	60
41	<sc>HE</sc>4 and <sc>CA</sc>125 levels in the preoperative assessment of endometrial cancer patients: a prospective multicenter study (<sc>ENDOMET</sc>). <i>Acta Obstetricia Et Gynecologica Scandinavica</i> , 2013, 92, 1313-1322.	2.8	60
42	Inflammatory Bowel Disease and Small Bowel Cancer Risk, Clinical Characteristics, and Histopathology: A Population-Based Study. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1900-1907.e2.	4.4	59
43	The prevalence of <sc>EGFR</sc> mutations in non-small cell lung cancer in an unselected Caucasian population. <i>Apmis</i> , 2015, 123, 108-115.	2.0	55
44	Common alleles in candidate susceptibility genes associated with risk and development of epithelial ovarian cancer. <i>International Journal of Cancer</i> , 2011, 128, 2063-2074.	5.1	54
45	Smoking and Overweight: Negative Prognostic Factors in Stage III Epithelial Ovarian Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006, 15, 798-803.	2.5	50
46	Influence of 2-(18F) Fluoro-2-Deoxy-d-Glucose Positron Emission Tomography/Computed Tomography on Recurrent Ovarian Cancer Diagnosis and on Selection of Patients for Secondary Cytoreductive Surgery. <i>International Journal of Gynecological Cancer</i> , 2009, 19, 600-604.	2.5	49
47	The Role of KRAS rs61764370 in Invasive Epithelial Ovarian Cancer: Implications for Clinical Testing. <i>Clinical Cancer Research</i> , 2011, 17, 3742-3750.	7.0	47
48	SUVmax of 18FDG PET/CT as a predictor of high-risk endometrial cancer patients. <i>Gynecologic Oncology</i> , 2013, 129, 298-303.	1.4	47
49	Human Papillomavirus in Head and Neck Squamous Cell Carcinoma of Unknown Primary Is a Common Event and a Strong Predictor of Survival. <i>PLoS ONE</i> , 2014, 9, e110456.	2.5	44
50	Association between Common Germline Genetic Variation in 94 Candidate Genes or Regions and Risks of Invasive Epithelial Ovarian Cancer. <i>PLoS ONE</i> , 2009, 4, e5983.	2.5	38
51	Identification and validation of potential prognostic and predictive miRNAs of epithelial ovarian cancer. <i>PLoS ONE</i> , 2018, 13, e0207319.	2.5	35
52	Clinical Implications of Intestinal Stem Cell Markers in Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2015, 14, 63-71.	2.3	34
53	Markers aiding the diagnosis of chondroid tumors: an immunohistochemical study including osteonectin, bcl-2, actin, calponin, D240 (podoplanin), mdm2, CD117 (c-kit), and YKL40. <i>Apmis</i> , 2009, 117, 518-525.		33
54	Standardized FDG uptake as a prognostic variable and as a predictor of incomplete cytoreduction in primary advanced ovarian cancer. <i>Acta Oncologica</i> , 2011, 50, 415-419.	1.8	33

#	ARTICLE	IF	CITATIONS
55	Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium. <i>Clinical Cancer Research</i> , 2015, 21, 5264-5276.	7.0	33
56	Relapse and disease specific survival in 1143 Danish women diagnosed with borderline ovarian tumours (BOT). <i>Gynecologic Oncology</i> , 2016, 142, 50-53.	1.4	33
57	Adenoid cystic carcinomas of the salivary gland, lacrimal gland, and breast are morphologically and genetically similar but have distinct microRNA expression profiles. <i>Modern Pathology</i> , 2018, 31, 1211-1225.	5.5	33
58	Pelvic inflammatory disease and risk of invasive ovarian cancer and ovarian borderline tumors. <i>Cancer Causes and Control</i> , 2013, 24, 1459-1464.	1.8	32
59	Assessment of Hepatocyte Growth Factor in Ovarian Cancer Mortality. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 1638-1648.	2.5	31
60	The prognostic value of dividing epithelial ovarian cancer into type I and type II tumors based on pathologic characteristics. <i>Gynecologic Oncology</i> , 2015, 136, 205-211.	1.4	30
61	Current status on microRNAs as biomarkers for ovarian cancer. <i>Apmis</i> , 2016, 124, 337-355.	2.0	30
62	Molecular signatures of thyroid follicular neoplasia. <i>Endocrine-Related Cancer</i> , 2010, 17, 691-708.	3.1	28
63	Positron Emission Tomography/Computed Tomography Predictors of Overall Survival in Stage IIIC/IV Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2012, 22, 1163-1169.	2.5	28
64	Recent alcohol consumption and risk of incident ovarian carcinoma: a pooled analysis of 5,342 cases and 10,358 controls from the Ovarian Cancer Association Consortium. <i>BMC Cancer</i> , 2013, 13, 28.	2.6	28
65	History of hypertension, heart disease, and diabetes and ovarian cancer patient survival: evidence from the ovarian cancer association consortium. <i>Cancer Causes and Control</i> , 2017, 28, 469-486.	1.8	28
66	PAPP-A proteolytic activity enhances IGF bioactivity in ascites from women with ovarian carcinoma. <i>Oncotarget</i> , 2015, 6, 32266-32278.	1.8	28
67	Accuracy of self-reported family history of cancer in a large case-control study of ovarian cancer. <i>Cancer Causes and Control</i> , 2008, 19, 469-479.	1.8	27
68	MicroRNA Expression in Formalin-fixed Paraffin-embedded Cancer Tissue: Identifying Reference MicroRNAs and Variability. <i>BMC Cancer</i> , 2015, 15, 1024.	2.6	27
69	Improved migration of tumor ascites lymphocytes to ovarian cancer microenvironment by CXCR2 transduction. <i>Oncolmmunology</i> , 2018, 7, e1412029.	4.6	27
70	Early Laboratory Diagnosis of COVID-19 by Antigen Detection in Blood Samples of the SARS-CoV-2 Nucleocapsid Protein. <i>Journal of Clinical Microbiology</i> , 2021, 59, e0100121.	3.9	27
71	Proteomic biomarkers for overall and progression-free survival in ovarian cancer patients. <i>Proteomics - Clinical Applications</i> , 2010, 4, 940-952.	1.6	26
72	Risk factors for brain metastases in patients with metastatic colorectal cancer. <i>Acta Oncologica</i> , 2017, 56, 639-645.	1.8	26

#	ARTICLE	IF	CITATIONS
73	The PRKD1 E710D hotspot mutation is highly specific in separating polymorphous adenocarcinoma of the palate from adenoid cystic carcinoma and pleomorphic adenoma on FNA. <i>Cancer Cytopathology</i> , 2018, 126, 275-281.	2.4	26
74	MicroRNA dysregulation in adenoid cystic carcinoma of the salivary gland in relation to prognosis and gene fusion status: a cohort study. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 473, 329-340.	2.8	26
75	Methylation and ovarian cancer: Can DNA methylation be of diagnostic use? (Review). <i>Molecular and Clinical Oncology</i> , 2019, 10, 323-330.	1.0	26
76	Use of dairy products, lactose, and calcium and risk of ovarian cancer – Results from a Danish case-control study. <i>Acta Oncologica</i> , 2012, 51, 454-464.	1.8	25
77	Cigarette smoking is associated with adverse survival among women with ovarian cancer: Results from a pooled analysis of 19 studies. <i>International Journal of Cancer</i> , 2017, 140, 2422-2435.	5.1	25
78	Genetic Variation in <i>TYMS</i> in the One-Carbon Transfer Pathway Is Associated with Ovarian Carcinoma Types in the Ovarian Cancer Association Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 1822-1830.	2.5	24
79	miR-21 Expression in Cancer Cells may Not Predict Resistance to Adjuvant Trastuzumab in Primary Breast Cancer. <i>Frontiers in Oncology</i> , 2014, 4, 207.	2.8	24
80	Coffee, tea, and caffeine consumption and risk of epithelial ovarian cancer and borderline ovarian tumors: Results from a Danish case-control study. <i>Acta Oncologica</i> , 2015, 54, 1144-1151.	1.8	24
81	SOX9 expression predicts relapse of stage II colon cancer patients. <i>Human Pathology</i> , 2016, 52, 38-46.	2.0	24
82	Associations between primary tumor <i>RAS</i> , <i>BRAF</i> and <i>PIK3CA</i> mutation status and metastatic site in patients with chemo-resistant metastatic colorectal cancer. <i>Acta Oncologica</i> , 2018, 57, 1057-1062.	1.8	24
83	Diagnostic plasma miRNA-profiles for ovarian cancer in patients with pelvic mass. <i>PLoS ONE</i> , 2019, 14, e0225249.	2.5	24
84	Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA. <i>Human Genetics</i> , 2014, 133, 481-497.	3.8	23
85	Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci. <i>British Journal of Cancer</i> , 2017, 116, 524-535.	6.4	23
86	Identification of bacteria using two degenerate 16S rDNA sequencing primers. <i>Microbiological Research</i> , 1999, 154, 23-26.	5.3	22
87	Comparison of proteomic biomarker panels in urine and serum for ovarian cancer diagnosis. <i>Proteomics - Clinical Applications</i> , 2010, 4, 304-314.	1.6	22
88	MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. <i>Mayo Clinic Proceedings</i> , 2018, 93, 307-320.	3.0	22
89	Preoperative CA125 as a prognostic factor in stage I epithelial ovarian cancer. <i>Apmis</i> , 2006, 114, 359-363.	2.0	21
90	Estrogen Receptor Beta rs1271572 Polymorphism and Invasive Ovarian Carcinoma Risk: Pooled Analysis within the Ovarian Cancer Association Consortium. <i>PLoS ONE</i> , 2011, 6, e20703.	2.5	21

#	ARTICLE	IF	CITATIONS
91	<scp>KRAS</scp> and <scp>BRAF</scp> mutations in anal carcinoma. <i>Apmis</i> , 2015, 123, 53-59.	2.0	20
92	Demographic Clinical and Prognostic Factors of Primary Ovarian Adenocarcinomas of Serous and Clear Cell Histologyâ€”A Comparative Study. <i>International Journal of Gynecological Cancer</i> , 2016, 26, 82-90.	2.5	20
93	The association between socioeconomic status and tumour stage at diagnosis of ovarian cancer: A pooled analysis of 18 case-control studies. <i>Cancer Epidemiology</i> , 2016, 41, 71-79.	1.9	20
94	Predictors of pretreatment CA125 at ovarian cancer diagnosis: a pooled analysis in the Ovarian Cancer Association Consortium. <i>Cancer Causes and Control</i> , 2017, 28, 459-468.	1.8	20
95	Use of analgesic drugs and risk of ovarian cancer: results from a Danish caseâ€”control study. <i>Acta Obstetricia Et Gynecologica Scandinavica</i> , 2012, 91, 1094-1102.	2.8	19
96	Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. <i>Human Genetics</i> , 2016, 135, 741-756.	3.8	19
97	A novel index for preoperative, non-invasive prediction of macro-radical primary surgery in patients with stage IIIâ€”IV ovarian cancerâ€”a part of the Danish prospective pelvic mass study. <i>Tumor Biology</i> , 2016, 37, 12619-12626.	1.8	19
98	Oncomineâ„¢ Comprehensive Assay v3 vs. Oncomineâ„¢ Comprehensive Assay Plus. <i>Cancers</i> , 2021, 13, 5230.	3.7	19
99	Risk of ovarian cancer in women with first-degree relatives with cancer. <i>Acta Obstetricia Et Gynecologica Scandinavica</i> , 2009, 88, 449-456.	2.8	18
100	High specificity but low sensitivity of mutation-specific antibodies against EGFR mutations in non-small-cell lung cancer. <i>Modern Pathology</i> , 2014, 27, 1590-1598.	5.5	18
101	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. <i>Gynecologic Oncology</i> , 2016, 141, 386-401.	1.4	18
102	A Highly Sensitive Quantitative Real-Time PCR Assay for Determination of Mutant JAK2 Exon 12 Allele Burden. <i>PLoS ONE</i> , 2012, 7, e33100.	2.5	18
103	A novel monoclonal antibody to a defined peptide epitope in MUC16. <i>Glycobiology</i> , 2015, 25, 1172-1182.	2.5	17
104	Intra-tumor heterogeneity of microRNA-92a, microRNA-375 and microRNA-424 in colorectal cancer. <i>Experimental and Molecular Pathology</i> , 2016, 100, 125-131.	2.1	17
105	Demographic, Clinical, and Prognostic Factors of Ovarian Clear Cell Adenocarcinomas According to Endometriosis Status. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 1804-1812.	2.5	17
106	Next Generation Sequencing Technology in the Clinic and Its Challenges. <i>Cancers</i> , 2021, 13, 1751.	3.7	17
107	Consortium analysis of gene and geneâ€”folate interactions in purine and pyrimidine metabolism pathways with ovarian carcinoma risk. <i>Molecular Nutrition and Food Research</i> , 2014, 58, 2023-2035.	3.3	16
108	History of thyroid disease and survival of ovarian cancer patients: results from the Ovarian Cancer Association Consortium, a brief report. <i>British Journal of Cancer</i> , 2017, 117, 1063-1069.	6.4	16

#	ARTICLE	IF	CITATIONS
109	Early metastatic colorectal cancers show increased tissue expression of miR-17/92 cluster members in the invasive tumor front. <i>Human Pathology</i> , 2018, 80, 231-238.	2.0	16
110	Evidence of No Association Between Human Papillomavirus and Breast Cancer. <i>Frontiers in Oncology</i> , 2018, 8, 209.	2.8	15
111	Digital image analysis of pan-cytokeratin stained tumor slides for evaluation of tumor budding in pT1/pT2 colorectal cancer: Results of a feasibility study. <i>Pathology Research and Practice</i> , 2018, 214, 1273-1281.	2.3	15
112	The prevalence of EBV and CMV DNA in epithelial ovarian cancer. <i>Infectious Agents and Cancer</i> , 2019, 14, 7.	2.6	15
113	Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival. <i>Gynecologic Oncology</i> , 2020, 158, 702-709.	1.4	15
114	Feasibility of Serodiagnosis of Ovarian Cancer by Mass Spectrometry. <i>Analytical Chemistry</i> , 2009, 81, 1907-1913.	6.5	14
115	Topoisomerase-1 gene copy aberrations are frequent in patients with breast cancer. <i>International Journal of Cancer</i> , 2015, 137, 2000-2006.	5.1	14
116	Searching for new biomarkers in ovarian cancer patients: Rationale and design of a retrospective study under the Mermaid III project. <i>Contemporary Clinical Trials Communications</i> , 2017, 8, 167-174.	1.1	14
117	Deep sequencing of human papillomavirus positive loco-regionally advanced oropharyngeal squamous cell carcinomas reveals novel mutational signature. <i>BMC Cancer</i> , 2018, 18, 640.	2.6	14
118	Development of a metastatic fluorescent Lewis Lung carcinoma mouse model: Identification of mRNAs and microRNAs involved in tumor invasion. <i>Gene</i> , 2013, 517, 72-81.	2.2	13
119	Remodeling of the Tumor Microenvironment Predicts Increased Risk of Cancer in Postmenopausal Women: The Prospective Epidemiologic Risk Factor (PERF I) Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 1348-1355.	2.5	13
120	Use of common analgesic medications and ovarian cancer survival: results from a pooled analysis in the Ovarian Cancer Association Consortium. <i>British Journal of Cancer</i> , 2017, 116, 1223-1228.	6.4	13
121	High-Throughput Sequencing-Based Investigation of Viruses in Human Cancers by Multienrichment Approach. <i>Journal of Infectious Diseases</i> , 2019, 220, 1312-1324.	4.0	13
122	Circulating Antinuclear Antibodies in Patients with Pelvic Masses Are Associated with Malignancy and Decreased Survival. <i>PLoS ONE</i> , 2012, 7, e30997.	2.5	13
123	DNA sequencing of cytopathologically inconclusive EUS-FNA from solid pancreatic lesions suspicious for malignancy confirms EUS diagnosis. <i>Endoscopic Ultrasound</i> , 2020, 9, 37.	1.5	13
124	The variation of risk estimates through pregnancy in second trimester maternal serum screening for Down syndrome. <i>Prenatal Diagnosis</i> , 2002, 22, 385-387.	2.3	12
125	Gene Expression Profiles as Prognostic Markers in Women With Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2009, 19, 1205-1213.	2.5	12
126	Prognostic value of tissue protein expression levels of MIB-1 (Ki67) in Danish ovarian cancer patients. From the MALOVA™ ovarian cancer study. <i>Apmis</i> , 2013, 121, 1177-1186.	2.0	12



#	ARTICLE	IF	CITATIONS
127	Cell of origin predicts outcome to treatment with etoposide-containing chemotherapy in young patients with high-risk diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 2039-2046.	1.3	12
128	Investigating intra-tumor heterogeneity and expression gradients of miR-21, miR-92a and miR-200c and their potential of predicting lymph node metastases in early colorectal cancer. <i>Experimental and Molecular Pathology</i> , 2016, 101, 187-196.	2.1	12
129	Sample handling for mass spectrometric proteomic investigations of human urine. <i>Proteomics - Clinical Applications</i> , 2008, 2, 1184-1193.	1.6	11
130	Clinical validation of chemotherapy predictors developed on global microRNA expression in the NCI60 cell line panel tested in ovarian cancer. <i>PLoS ONE</i> , 2017, 12, e0174300.	2.5	11
131	Effect of inhibition of CBP-coactivated $\beta$ -catenin-mediated Wnt signalling in uremic rats with vascular calcifications. <i>PLoS ONE</i> , 2018, 13, e0201936.	2.5	11
132	Gene expression profile association with poor prognosis in epithelial ovarian cancer patients. <i>Scientific Reports</i> , 2021, 11, 5438.	3.3	11
133	<scp>HPV</scp> genotype distribution in older Danish women undergoing surgery due to cervical cancer. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2015, 94, 1262-1268.	2.8	10
134	Hyperplastic polyps of the colon and rectum " reclassification, <scp>BRAF</scp> and <scp>KRAS</scp> status in index polyps and subsequent colorectal carcinoma. <i>Apmis</i> , 2015, 123, 298-304.	2.0	10
135	HE4 as a predictor of adjuvant chemotherapy resistance and survival in patients with epithelial ovarian cancer. <i>Apmis</i> , 2016, 124, 1038-1045.	2.0	10
136	Epidermal growth factor receptor exon 20 p.S768I mutation in non-small cell lung carcinoma: A case report combined with a review of the literature and investigation of clinical significance. <i>Oncology Letters</i> , 2016, 11, 393-398.	1.8	10
137	Assessment of Multifactor Gene"Environment Interactions and Ovarian Cancer Risk: Candidate Genes, Obesity, and Hormone-Related Risk Factors. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 780-790.	2.5	10
138	History of Comorbidities and Survival of Ovarian Cancer Patients, Results from the Ovarian Cancer Association Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 1470-1473.	2.5	10
139	Optimized Biobanking Procedures for Preservation of RNA in Tissue: Comparison of Snap-Freezing and RNAlater-Fixation Methods. <i>Biopreservation and Biobanking</i> , 2019, 17, 562-569.	1.0	10
140	Genomic Sub-Classification of Ovarian Clear Cell Carcinoma Revealed by Distinct Mutational Signatures. <i>Cancers</i> , 2021, 13, 5242.	3.7	10
141	The Diagnostic Value of Circulating Cell-Free HPV DNA in Plasma from Cervical Cancer Patients. <i>Cells</i> , 2022, 11, 2170.	4.1	10
142	Annexin A2 and S100A10 as Candidate Prognostic Markers in Epithelial Ovarian Cancer. <i>Anticancer Research</i> , 2019, 39, 2475-2482.	1.1	9
143	Evaluation of analytical accuracy of HER2 status in patients with breast cancer. <i>Apmis</i> , 2020, 128, 573-582.	2.0	9
144	Genome-Wide Association Study for Ovarian Cancer Susceptibility Using Pooled DNA. <i>Twin Research and Human Genetics</i> , 2012, 15, 615-623.	0.6	8

#	ARTICLE	IF	CITATIONS
145	Comparison of Fluorescence In Situ Hybridization and Chromogenic In Situ Hybridization for Low and High Throughput HER2 Genetic Testing. <i>International Journal of Breast Cancer</i> , 2013, 2013, 1-5.	1.2	8
146	Approaches to the detection of ovarian cancer. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2016, 76, S49-S53.	1.2	7
147	Noncoding RNA (ncRNA) Profile Association with Patient Outcome in Epithelial Ovarian Cancer Cases. <i>Reproductive Sciences</i> , 2021, 28, 757-765.	2.5	7
148	The somatic mode: doing good in targeted cancer therapy. <i>New Genetics and Society</i> , 2021, 40, 178-198.	1.2	7
149	DNA Methylation in Ovarian Tumors – a Comparison Between Fresh Tissue and FFPE Samples. <i>Reproductive Sciences</i> , 2021, 28, 3212-3218.	2.5	7
150	Analysis of HOXA9 methylated ctDNA in ovarian cancer using sense-antisense measurement. <i>Clinica Chimica Acta</i> , 2021, 522, 152-157.	1.1	7
151	Serum tetranectin is a significant prognostic marker in ovarian cancer patients. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2010, 89, 190-198.	2.8	6
152	Serum YKL-40 and uterine artery Doppler – a prospective cohort study, with focus on preeclampsia and small-for-gestational-age. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2014, 93, 817-824.	2.8	6
153	Tetranectin positive expression in tumour tissue leads to longer survival in Danish women with ovarian cancer. Results from the “Malova”™ ovarian cancer study. <i>Apmis</i> , 2015, 123, 401-409.	2.0	6
154	Impact of PD-L1 and T-cell inflamed gene expression profile on survival in advanced ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1034-1042.	2.5	6
155	A Proteomics Panel for Predicting Optimal Primary Cytoreduction in Stage III/IV Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2009, 19, 1535-1538.	2.5	5
156	Polymorphisms in Stromal Genes and Susceptibility to Serous Epithelial Ovarian Cancer: A Report from the Ovarian Cancer Association Consortium. <i>PLoS ONE</i> , 2011, 6, e19642.	2.5	5
157	(GT) <sub>n</sub> Repeat Polymorphism in Heme Oxygenase-1 (HO-1) Correlates with Clinical Outcome after Myeloablative or Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation. <i>PLoS ONE</i> , 2016, 11, e0168210.	2.5	5
158	Adjustment of serum HE4 to reduced glomerular filtration and its use in biomarker-based prediction of deep myometrial invasion in endometrial cancer. <i>Oncotarget</i> , 2017, 8, 108213-108222.	1.8	5
159	The prognostic value of polycomb group protein B-cell specific moloney murine leukemia virus insertion site 1 in stage II colon cancer patients. <i>Apmis</i> , 2016, 124, 541-546.	2.0	4
160	Prognostic impact of histological review of high-grade endometrial carcinomas in a large Danish cohort. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 479, 507-514.	2.8	4
161	MicroRNA characteristics in epithelial ovarian cancer. <i>PLoS ONE</i> , 2021, 16, e0252401.	2.5	4
162	Integrated microRNA and mRNA signatures associated with overall survival in epithelial ovarian cancer. <i>PLoS ONE</i> , 2021, 16, e0255142.	2.5	4

#	ARTICLE	IF	CITATIONS
163	Exome sequencing of 22 genes using tissue from patients with biliary tract cancer. <i>Apmis</i> , 2020, 128, 3-9.	2.0	3
164	Targeting the Supply Lines of Cancer – A Possible Strategy for Combating the Disease?. <i>Anticancer Research</i> , 2021, 41, 2737-2744.	1.1	3
165	CA-125 Levels Are Predictive of Survival in Low-Grade Serous Ovarian Cancer – A Multicenter Analysis. <i>Cancers</i> , 2022, 14, 1954.	3.7	3
166	Diagnostic accuracy of risk of malignancy index in predicting complete tumor removal at primary debulking surgery for ovarian cancer patients. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2013, 92, 721-726.	2.8	2
167	The prospect of discovering new biomarkers for ovarian cancer based on current knowledge of susceptibility loci and genetic variation (Review). <i>International Journal of Molecular Medicine</i> , 2019, 44, 1599-1608.	4.0	2
168	Assessment of recurrence rate and risk factors of relapse in stage in IA vulvar carcinoma. <i>Gynecologic Oncology</i> , 2022, 164, 543-549.	1.4	2
169	Organoids and epithelial ovarian cancer – a future tool for personalized treatment decisions?. <i>Molecular and Clinical Oncology</i> , 2021, 16, 29.	1.0	2
170	Preoperative predictors of inguinal lymph node metastases in vulvar cancer – A nationwide study. <i>Gynecologic Oncology</i> , 2022, 165, 420-427.	1.4	2
171	Serum tetranectin as a preoperative indicator for postoperative complications in Danish ovarian cancer patients. <i>Gynecologic Oncology</i> , 2010, 117, 446-450.	1.4	1
172	Ovarian Clear Cell Carcinoma: From Morphology to Molecular Biology. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2019, 27, 631-636.	1.2	1
173	Incidents in Molecular Pathology: Frequency and Causes During Routine Testing. <i>Archives of Pathology and Laboratory Medicine</i> , 2021, 145, 1270-1279.	2.5	1
174	Impact of microRNA miR-345 in blood on survival and response in 144 patients with metastatic colorectal cancer treated with third-line cetuximab and irinotecan.. <i>Journal of Clinical Oncology</i> , 2012, 30, 451-451.	1.6	1
175	Prostate Cancer Susceptibility Polymorphism rs2660753 Is Not Associated with Invasive Ovarian Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 1028-1031.	2.5	0
176	Lack of topoisomerase copy number changes in patients with de novo and relapsed diffuse large B-cell lymphoma. <i>Experimental Hematology</i> , 2015, 43, 534-536.	0.4	0
177	FP375EFFECT OF WNT-INHIBITION ON ESTABLISHED VASCULAR CALCIFICATION IN UREMIC RATS. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i159-i159.	0.7	0
178	The nationwide Danish CancerBiobank: Future possibilities.. <i>Journal of Clinical Oncology</i> , 2014, 32, e22196-e22196.	1.6	0
179	Outcome of cetuximab plus irinotecan in relation to <i>RAS</i> and <i>BRAF</i> mutational status in patients with colorectal cancer prior treated with a fluoropyrimidine, oxaliplatin and irinotecan.. <i>Journal of Clinical Oncology</i> , 2016, 34, e15115-e15115.	1.6	0